Imunon, Inc. 8-K

What Happened

• Imunon, Inc. (IMNN) filed a prospectus supplement on March 23, 2026, to register an additional $7,000,000 of its common stock under its At‑The‑Market Offering Agreement with H.C. Wainwright & Co., LLC. The original Sales Agreement is dated May 25, 2022, and was amended May 15, 2024.
• The prospectus supplement increases the aggregate registration from $10,000,000 to $17,000,000. The company has previously sold $4,797,848 of common stock under the Sales Agreement.

Key Details

• Additional registration: $7,000,000 added (filed March 23, 2026).
• Aggregate registration: $17,000,000 total available under the Sales Agreement.
• Prior sales through ATM: $4,797,848 sold to date.
• Remaining capacity: Approximately $12,202,152 of registration capacity remains ($17,000,000 − $4,797,848).
• Sales agent: H.C. Wainwright & Co., LLC; legal opinion on the offering filed as Exhibit 5.1.

Why It Matters

• This filing gives Imunon flexibility to raise capital incrementally through its ATM program. If the company sells shares under this registration, it will increase outstanding shares, which can dilute existing shareholders.
• For investors, the important things to watch are future 8‑Ks or Form 424B prospectus supplements showing actual sales amounts and timing, and any impact those sales have on share count and market price.